| Name | ARQ 621 |
| Description | ARQ 621 is an allosteric, and selective Eg5 mitotic motor protein inhibitor. Phase 1. |
| In vitro | ARQ 621 demonstrates anti-tumor activity against a wide range of human cancer cell lines in vitro, including colon, lung, endometrial, bladder, and hematologic cancer cell lines, with significantly less cytotoxicity against hematopoietic cells. [1] |
| In vivo | ARQ 621, as a novel clinical stage drug candidate, inhibits a number of xenografts grown in athymic mice, such as pancreatic, breast, prostate, and ovarian carcinomas with no hematological changes. Furthermore, for ARQ 621, there is no envidence of bone marrow toxicity in pre-clinical mouse efficacy models or safety studies in rats and dogs. [1] |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 93 mg/mL (168.3 mM)
DMSO : 93 mg/mL (168.3 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | motor | ARQ 621 | inhibit | cell | division | ARQ621 | protein | Inhibitor | microtubule | Kinesin | Anti-tumor | Eg5 | ARQ-621 |
| Inhibitors Related | Eg5-IN-1 | Eg5 Inhibitor V, trans-24 | AZD-4877 | UMK57 | BAY1217389 | BRD9876 | Paprotrain | SB-743921 hydrochloride | S-trityl-L-Cysteine | Empesertib | MPI-0479605 | CW-069 |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
